Table 4.
Mean baseline and 6-month follow-up values for outcome measures, stratified by number of facility-based classes
| Outcome and adherence subgroup | Baseline | 6-month follow-up | 6-month Δ (95% CI) relative to controls | Pb | |
|---|---|---|---|---|---|
| N | Mean (SD) | ||||
| Quality of life measures | |||||
| Overall QOL: FACT-G | 0.30 | ||||
| Controls | 27 | 87.8 (14.2) | 87.7 (14.9) | Ref | |
| 1–13 | 9 | 85.4 (6.8) | 86.5 (10.4) | +1.0 (−5.1, +7.0) | |
| 14–23 | 11 | 92.3 (10.3) | 91.9 (11.1) | +0.2 (−5.4, +5.9) | |
| 24–61 | 10 | 88.7 (9.9) | 92.0 (11.7) | +3.5 (−2.3, +9.3) | |
| FACIT-Breast cancer subscale | 0.006 | ||||
| Controls | 27 | 25.4 (5.2) | 25.2 (5.5) | Ref | |
| 1–13 | 9 | 25.1 (1.8) | 24.4 (3.6) | −0.6 (−3.1, +1.9) | |
| 14–23 | 11 | 26.9 (4.8) | 27.7 (4.5) | +1.4 (−1.0, +3.7) | |
| 24–61 | 10 | 24.3 (4.8) | 27.9 (3.8) | +3.5 (+1.1, +6.0) | |
| Fatigue | 0.10 | ||||
| FACIT-Fatigue | |||||
| Controls | 27 | 43.2 (8.5) | 43.1 (10.3) | Ref | |
| 1–13 | 9 | 41.3 (7.5) | 43.2 (5.8) | +1.6 (−2.6, +5.8) | |
| 14–23 | 11 | 45.3 (5.0) | 45.1 (5.0) | +0.2 (−3.8, +4.1) | |
| 24–61 | 10 | 42.3 (4.6) | 46.6 (5.1) | +4.2 (+0.1, +8.2) | |
| Anthropometric measures | |||||
| Weight (kg) | 0.34 | ||||
| Controls | 27 | 81.3 (13.6) | 81.3 (14.3) | Ref | |
| 1–13 | 7 | 80.6 (7.6) | 81.6 (11.6) | +1.0 (−1.6, +3.7) | |
| 14–23 | 11 | 75.5 (9.3) | 75.3 (9.2) | +0.2 (−2.1, +2.5) | |
| 24–61 | 10 | 85.6 (15.3) | 87.2 (17.0) | +1.3 (−1.1, +3.6) | |
| Body mass index (kg/m2) | 0.41 | ||||
| Controls | 27 | 29.5 (4.3) | 29.5 (4.7) | Ref | |
| 1–13 | 7 | 30.1 (2.7) | 30.5 (3.6) | +0.3 (−0.7, +1.2) | |
| 14–23 | 11 | 28.0 (2.8) | 28.0 (2.7) | 0.0 (−0.8, +0.8) | |
| 24–61 | 10 | 30.0 (4.9) | 30.5 (5.3) | +0.4 (−0.4, +1.3) | |
| Waist circumference (cm) | 0.12 | ||||
| Controls | 27 | 91.1 (8.9) | 92.7 (10.5) | Ref | |
| 1–13 | 7 | 100.1 (7.5) | 96.8 (11.5) | −5.4 (−9.8, −1.0) | |
| 14–23 | 11 | 91.9 (5.5) | 91.3 (7.0) | −2.2 (−5.7, +1.2) | |
| 24–61 | 10 | 93.3 (7.1) | 92.3 (7.6) | −2.7 (−6.3, +0.9) | |
| Hip circumference (cm) | 0.27 | ||||
| Controls | 27 | 112.7 (8.4) | 113.9 (10.3) | Ref | |
| 1–13 | 7 | 112.3 (9.3) | 112.9 (10.0) | −0.6 (−4.2, +3.0) | |
| 14–23 | 11 | 109.9 (7.3) | 109.4 (8.9) | −1.4 (−4.5, +1.6) | |
| 24–61 | 10 | 116.8 (10.1) | 116.9 (11.0) | −1.4 (−4.6, +1.8) | |
| Non-yoga physical activity (MET-hrs per wk) | 0.64 | ||||
| Controls | 27 | 12.4 (12.8) | 12.0 (13.6) | Ref | |
| 1–13 | 9 | 14.9 (8.8) | 17.7 (7.2) | +3.2 (−5.6, +12.0) | |
| 14–23 | 11 | 13.4 (12.1) | 11.7 (13.7) | −1.2 (−9.4, +6.9) | |
| 24–61 | 10 | 16.9 (14.0) | 21.9 (28.9) | +5.5 (−3.0, +14.0) | |
Abbreviations: CI, confidence interval; FACT-G, Functional Assessment of Cancer Therapy-General; FACIT, Functional Assessment of Chronic Illness Therapy; MET, metabolic equivalent task; QOL, quality of life; SD, standard deviation.
b
P value for trend test of baseline-to-6-month differences across groups (control, low, medium, high), controlling for baseline value of outcome measures.